Logo Mark
Publications

Frontiers in Oncology

All Publications

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

Clinical Imetelstat: MFImetelstat
Frontiers in Oncology

Olschok, et. al.

[facetwp facet="publication_load_more"]